MARYLAND LIFE SCIENCES:
MARYLAND AT BIO
Get to Know Maryland
Maryland has its very own ecosystem of life sciences companies, making the state an impressive hub for scientific innovation. Maryland’s life sciences industry not only stands out among other states, but also shines internationally. Our team, along with a delegation of Maryland companies, will represent Maryland at the BIO International Convention on June 22-25, 2026. Visit the Commerce team at Booth No. 4835 to see what Maryland offers businesses. Below, you can learn more about the leaders behind some life sciences companies that proudly call Maryland home and find their direct contact info for those interested in partnering.
Connect with the Companies
A delegation of Maryland companies will be exhibiting within the Maryland booth. Explore them here and find contact information to coordinate meetings.
AAVnerGene Inc. focuses exclusively on developing advanced AAV technologies that support the growing fields of gene and cell therapy. Their team of highly trained scientists is creating next‑generation production systems designed to make AAV manufacturing more reliable, efficient, and high‑quality.
Contact: Daozhan Yu
Adventris Pharmaceuticals is developing a best-in-class “off-the-shelf” engineered KRAS-Plus therapeutic cancer vaccine. Their lead program targets common KRAS mutations that have been optimized using our proprietary antigen engineering technology (licensed from Johns Hopkins) to substantially strengthen the naturally weak T cell responses to these key mutations.
Contact: Jenny Herbach
At Caleo Biotechnologies, advances patient-derived, immune-competent tissue models to enable predictive preclinical development for fibrotic and inflammatory diseases.
Contact: Samaneh Kamali
Elixirgen Therapeutics develops life-changing therapies, focusing on rare diseases and aging-associated diseases using their cutting-edge technologies.
Contact: Aki Ko
Fina Biosolutions is a conjugate vaccine R&D company. Our technology is used worldwide in licensed and pre clinical conjugate vaccines. Their FinaXpress E coli platform is used to make conjugate vaccine carrier proteins and therapeutics.
Contact: Andrew Lees
Fzata, Inc.’s. oral, live bioengineered probiotic yeast medicines (BioPYM) platform will revolutionize biologic therapeutics manufacturing, distribution, and no cold-chain storage as well as needle-free administration, patient compliance and safety. Their FZ002 lead candidate for C. diff infection is on target for IND submission May 2026. The phase 1 clinical trial (sponsored by NIH/NIAID/DMID) is on track to begin enrollment summer 2026 and is intended to demonstrate platform safety and therapeutic activity.
Contact: Elizabeth Smith
Irazu Oncology is a preclinical-stage biotech company developing IRZ-03, a first-in-class multimodal cancer immunotherapy built on a proprietary outer membrane vesicle (OMV) platform licensed from the University of Maryland. IRZ-03 is designed to simultaneously target tumor cells and reverse the immunosuppressive tumor microenvironment, addressing a critical unmet need for checkpoint inhibitor-refractory patients in the $44.7B cancer immunotherapy market.
Contact: Jeffrey Stoval
KaloCyte is a pre-clinical biotech startup developing ErythroMer, a novel artificial red blood cell (RBC) substitute that can be freeze-dried for long-term storage without refrigeration and used for pre-hospital treatment of severe bleeding when blood is unavailable. KaloCyte is currently seeking investors for a $5M Series Seed round to fund development of our artificial RBC substitute through IND filing.
Contact: Elaine Haynes
Nanost is building a handheld, AI-ready health infrastructure platform that delivers rapid, multiplex protein detection at the point of care. Their heat-stable, nanobody-integrated microfluidic cartridges eliminate cold chain and reduce consumable costs to under $2, enabling scalable diagnostics anywhere.
Contact: Norelle Wildburger
Neuroene Therapeutics Inc. is developing proprietary brain-penetrative, mitochondrial-protective small molecules for neurological diseases and toxic exposures.
Contact: Sherine Chan
Pinco Biotherapeutics is pioneering a novel DNA plasmid-based therapy that targets the Nav1.7 sodium channel to develop effective, longer-lasting, and precisely tunable therapeutics for neuropathic pain without the addiction risks and side effects associated with opioids.
Contact: Scott Alpizar
Precision Medicine Care (PMC) employs state of art technologies to deliver advanced clinical genomic diagnostic testing. Their clinical laboratory is accredited by CAP and certified by CLIA for performing high complexity tests.
Contact: Sherry Dadgar
Remedy Plan Therapeutics is a clinical-stage biotech company focused on developing NAMPT inhibitors for patients with hematological malignancies and solid tumors. Their lead asset, RPT1G, is a novel, small-molecule NAMPT inhibitor that solves a decades-old medical-science puzzle: targeting NAD synthesis in cancer cells without damaging healthy cells.
Contact: Greg Crimmins
SereNeuro Therapeutics SereNeuro Therapeutics is a preclinical biotechnology company developing non-opioid pain therapies with a novel approach to chronic pain management and joint tissue preservation. Their lead candidate SN101 is a first-in-class induced pluripotent stem cell (iPSC)-derived therapy.
Contact: Daniel Saragnese
VerImmune Inc. is an IND-enabling biotechnology company developing a self-assembling Virus-inspired Particle (ViP™) platform for targeted delivery of diverse therapeutic payloads across oncology, autoimmunity, and animal health. Its lead program, VERI-101, is a first-in-class immuno-oncology approach that redirects pre-existing CMV-specific T-cell immunity to eliminate solid and metastatic tumors in a tumor-type-agnostic manner, as monotherapy or in combination with standard of care
Contact: Joshua Wang
Maryland’s Life Sciences Sector
Life sciences companies need a robust scientific and technical community behind them. Here in Maryland, we call that community our innovation ecosystem, and it’s unlike anything else you’ll find in the U.S. What makes our ecosystem so special? Maryland is home to the FDA, NIH, and two times more federal labs than any other state. Here, find renowned universities, a highly trained scientific workforce, and initiatives designed to bolster innovation and success in life sciences.
Maryland’s Delegation
AAVnerGene focuses exclusively on developing advanced AAV technologies that support the growing fields of gene and cell therapy.
Adventris is developing a best-in-class “off-the-shelf” engineered KRAS-Plus therapeutic cancer vaccine.
Caleo Biotechnologies develops the next generation of patient-derived models for preclinical studies of fibrotic diseases.
Elixirgen Therapeutics is a clinical-stage biotechnology company focused on treating rare diseases.
Fina Biosolutions is a conjugate vaccine R&D company.
Fzata’s oral, live bioengineered probiotic yeast medicines (BioPYM) platform will revolutionize biologic therapeutics manufacturing, distribution, and no cold-chain storage as well as needle-free administration, patient compliance and safety.
Irazu Oncology is developing next-generation cancer immunotherapies using its proprietary OMV platform to potentially enable more effective and accessible treatment options for cancer patients.
KaloCyte is a pre-clinical biotech startup developing ErythroMer, a bioengineered artificial red blood cell (RBC) substitute that can stored long-term, and used to treat severe bleeding.
Nanost is building a handheld, AI-ready health infrastructure platform that delivers rapid, multiplex protein detection at the point of care.
Neuroene is developing proprietary brain-penetrative, mitochondrial-protective small molecules for neurological diseases and toxic exposures.
PincoBio is pioneering a novel DNA plasmid-based therapy that targets the Nav1.7 sodium channel to develop effective, longer-lasting, and precisely tunable therapeutics for neuropathic pain.
Precision Medicine Care employs state of art technologies to deliver advanced clinical genomic diagnostic testing.
Remedy Plan Therapeutics is a clinical-stage biotech company focused on developing NAMPT inhibitors for patients with hematological malignancies and solid tumors.
SereNeuro Therapeutics is a unique, non-opioid cell therapy designed to treat chronic knee pain caused by osteoarthritis. It uses highly purified cells to target and relieve pain without the risks associated with opioids.
VerImmune is an IND-enabling biotechnology company developing a self-assembling Virus-inspired Particle (ViP™) platform for targeted delivery of diverse therapeutic payloads across oncology, autoimmunity, and animal health.
Get Exclusive Life Sciences Updates
Stay informed on life sciences & general business news in Maryland.
